Mitsui Global Investment
VC Fund
Menlo Park, United States
Mitsui Global Investment is a VC fund in Menlo Park focused on Biotechnology and Health Care. [Mitsui & Co. Global Investment](http://www.mitsui-global.com/en/) is a venture capital fund that focuses on early stage companies. Mitsui's expertise lies in helping companies build their business globally. Mitsui & Co. Global Investment Co. is an investment company as a division of the financial business, to invest in companies that significant growth is expected. The headquarters in Tokyo, and we are investing activities from a global perspective, as opposed to complete in each country and a network of offices in Silicon Valley, Beijing, Mumbai, while also focusing on Japan and the United States China and India.
- Total investments:
- 135
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Mitsui Global Investment invests in
Stages Mitsui Global Investment invests in
Countries Mitsui Global Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $1.5M–$45M
- Series B
- $4.5M–$45M
- Series C
- $9.3M–$43M
Investment Focus
Industry
- Biotechnology 32 (24%)
- Health Care 25 (19%)
- Software 19 (14%)
- Medical 14 (10%)
- Manufacturing 12 (9%)
Stage
- Series C 33 (24%)
- Series A 26 (19%)
- Series B 26 (19%)
- Series D 15 (11%)
- Funding Round 15 (11%)
Country
- United States 76 (56%)
- China 7 (5%)
- Canada 5 (4%)
- Israel 5 (4%)
- India 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Atsushi Mizuno
Director
|
Director | Total investments: 0 | Find email | |
Caroline Pinkney
Analyst
|
Analyst | Total investments: 0 | Find email | |
Kinji Fuchikami
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Richard Cui
Principal
|
Principal | Total investments: 0 | Find email | |
Sanjay Pichaiah
Investment Director
|
Investment Director | Total investments: 7 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Optimizing cell therapy with spatial biology | $20M / Series A / May 27, 2026 | ||
| Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California. | $19M / Series A / Mar 09, 2026 | ||
| Rhino Federated Computing solves one of the biggest challenges in AI: seamlessly connecting siloed data through federated computing. The Rhino Federated Computing Platform (RhinoFCP) serves as the ‘data collaboration tech stack’, extending from providing computing resources to data preparation & discoverability, to model development &monitoring — all in a secure, privacy-preserving environment. To do this, Rhino FCP offers flexible architecture (multi-cloud and on-prem hardware), end-to-end data management workflows (multimodal data, schema definition, harmonization, and visualization), privacy enhancing technologies (e.g., differential privacy), and allows for the secure deployment of custom code & 3rd party applications via persistent data pipelines. Rhino is trusted by >60 leading organizations worldwide — including 14 of 20 of Newsweek’s ‘Best Smart Hospitals’ and top 20 global biopharma companies — and is leveraging this foundation for financial services, ecommerce, and beyond. The company is headquartered in Boston, with an R&D center in Tel Aviv. | $11.3M / Series A / Jan 27, 2026 | ||
| Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M / Series A / Sep 16, 2025 | ||
| Sage provides 24/7 support and simplified healthcare navigation, guiding patients through complex healthcare processes with empathetic conversation. | $45M / Series A / Jun 12, 2025 | ||
| Stately Bio is the trade-off between measuring cells and keeping them alive. Our patented ML technology measures cell identity, behavior, and maturation—all directly from live-cell, label-free imaging. | $12M / Seed / May 01, 2025 | ||
| Leash Biosciences engages in machine learning to solve medicinal chemistry. | $9.3M / Seed / Apr 05, 2024 | ||
| Leash Biosciences engages in machine learning to solve medicinal chemistry. | $9.3M / Seed / Apr 05, 2024 | ||
NVasc
|
NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels inthe retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans. | Oct 16, 2023 | |
| QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M / Series B / Mar 09, 2023 | ||
| See all 135 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mitsui Global Investment invest in?
Mitsui Global Investment invests primarily in Biotechnology, Health Care and Software startups, most often at Series C and Series A stage. Most of the 135 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Mitsui Global Investment invest in?
Mitsui Global Investment typically joins rounds of $1.5M–$45M at Series A, $4.5M–$45M at Series B and $9.3M–$43M at Series C. These are whole funding-round sizes, not Mitsui Global Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Mitsui Global Investment took part in.
How do I contact Mitsui Global Investment?
Public channels for Mitsui Global Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mitsui Global Investment?
The team at Mitsui Global Investment includes Atsushi Mizuno (Director), Caroline Pinkney (Analyst) and Kinji Fuchikami (Venture Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
